French biotech In­ven­ti­va's lead drug stum­bles in sys­temic scle­ro­sis study, ahead of NASH read­out

France’s In­ven­ti­va (Eu­ronext: $IVA) has suf­fered its first big set­back fol­low­ing its pub­lic list­ing in 2017. The com­pa­ny’s lead ex­per­i­men­tal drug, lan­i­fi­bra­nor, failed a mid-stage tri­al in pa­tients with a form of sys­temic scle­ro­sis (SSc) — a rare, chron­ic life-threat­en­ing dis­or­der in which the im­mune sys­tem at­tacks its own or­gans and is char­ac­ter­ized by a buildup of scar tis­sue — prompt­ing the Daix-based drug de­vel­op­er to aban­don the pro­gram for the in­di­ca­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER